James Marsh
Concepts (523)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardium | 47 | 2008 | 455 | 2.570 |
Why?
| Calcium Channels, L-Type | 17 | 2008 | 67 | 1.940 |
Why?
| Myocardial Contraction | 36 | 2010 | 113 | 1.510 |
Why?
| Calcium Channels | 13 | 2006 | 58 | 1.030 |
Why?
| Calcium | 33 | 2017 | 445 | 1.010 |
Why?
| Platelet Aggregation Inhibitors | 4 | 2017 | 192 | 0.970 |
Why?
| Stroke | 3 | 2019 | 532 | 0.910 |
Why?
| Genetic Therapy | 3 | 2009 | 120 | 0.900 |
Why?
| Platelet Function Tests | 2 | 2013 | 20 | 0.860 |
Why?
| Blood Platelets | 3 | 2017 | 262 | 0.830 |
Why?
| Purinergic P2Y Receptor Antagonists | 2 | 2013 | 33 | 0.830 |
Why?
| Ion Channels | 9 | 2009 | 76 | 0.770 |
Why?
| Rats | 37 | 2010 | 3613 | 0.760 |
Why?
| Myocytes, Cardiac | 8 | 2010 | 131 | 0.720 |
Why?
| Coronary Disease | 6 | 2004 | 145 | 0.720 |
Why?
| Brain Ischemia | 2 | 2019 | 173 | 0.680 |
Why?
| Fluorocarbons | 1 | 2019 | 53 | 0.660 |
Why?
| Heart | 16 | 2002 | 359 | 0.650 |
Why?
| Biomedical Research | 3 | 2018 | 244 | 0.640 |
Why?
| Neuroprotective Agents | 1 | 2019 | 132 | 0.620 |
Why?
| Research Personnel | 2 | 2018 | 69 | 0.620 |
Why?
| Receptors, Adrenergic, beta | 11 | 2000 | 44 | 0.610 |
Why?
| Muscle, Smooth, Vascular | 5 | 2006 | 145 | 0.610 |
Why?
| Cells, Cultured | 39 | 2008 | 1720 | 0.610 |
Why?
| Personnel Selection | 1 | 2017 | 28 | 0.610 |
Why?
| Internal Medicine | 1 | 2017 | 21 | 0.600 |
Why?
| Animals | 70 | 2012 | 14665 | 0.600 |
Why?
| Heart Ventricles | 21 | 2010 | 258 | 0.590 |
Why?
| Cardiovascular Diseases | 4 | 2020 | 480 | 0.570 |
Why?
| Leadership | 1 | 2017 | 115 | 0.560 |
Why?
| Faculty, Medical | 1 | 2017 | 102 | 0.560 |
Why?
| Calcium Channel Blockers | 8 | 2000 | 72 | 0.520 |
Why?
| Isoproterenol | 14 | 2002 | 60 | 0.500 |
Why?
| Physician's Role | 1 | 2014 | 56 | 0.490 |
Why?
| Sodium-Calcium Exchanger | 6 | 2004 | 8 | 0.480 |
Why?
| RNA, Messenger | 17 | 2005 | 1218 | 0.450 |
Why?
| Education, Medical | 1 | 2014 | 124 | 0.440 |
Why?
| Chest Pain | 1 | 2013 | 65 | 0.430 |
Why?
| Ticlopidine | 1 | 2013 | 58 | 0.430 |
Why?
| Rats, Sprague-Dawley | 20 | 2005 | 1765 | 0.420 |
Why?
| Coronary Artery Disease | 3 | 2012 | 307 | 0.410 |
Why?
| Angioplasty, Balloon, Coronary | 2 | 2012 | 153 | 0.390 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2010 | 153 | 0.380 |
Why?
| Acute Coronary Syndrome | 1 | 2012 | 88 | 0.370 |
Why?
| Excitation Contraction Coupling | 1 | 2010 | 3 | 0.370 |
Why?
| Transcription, Genetic | 6 | 2002 | 434 | 0.360 |
Why?
| Calcium Signaling | 1 | 2010 | 64 | 0.360 |
Why?
| Cardiomegaly | 3 | 1998 | 36 | 0.350 |
Why?
| Chick Embryo | 24 | 1993 | 84 | 0.340 |
Why?
| Hypertension | 5 | 2020 | 549 | 0.330 |
Why?
| Protein Subunits | 4 | 2008 | 84 | 0.320 |
Why?
| Promoter Regions, Genetic | 2 | 2002 | 526 | 0.320 |
Why?
| Emergency Service, Hospital | 1 | 2013 | 541 | 0.320 |
Why?
| Norepinephrine | 4 | 2002 | 123 | 0.310 |
Why?
| Troponin I | 1 | 2008 | 20 | 0.300 |
Why?
| Molecular Mimicry | 1 | 2008 | 69 | 0.300 |
Why?
| Sarcoplasmic Reticulum | 4 | 2010 | 25 | 0.300 |
Why?
| Humans | 35 | 2020 | 54277 | 0.290 |
Why?
| Drug Design | 1 | 2008 | 133 | 0.290 |
Why?
| Subarachnoid Hemorrhage | 1 | 2008 | 65 | 0.290 |
Why?
| Male | 32 | 2019 | 27576 | 0.280 |
Why?
| Time Factors | 9 | 2019 | 3211 | 0.270 |
Why?
| Muscle Proteins | 5 | 2007 | 315 | 0.260 |
Why?
| RNA Splice Sites | 1 | 2005 | 12 | 0.250 |
Why?
| Arteriosclerosis | 1 | 2004 | 60 | 0.250 |
Why?
| Testosterone | 6 | 2005 | 147 | 0.240 |
Why?
| Alternative Splicing | 1 | 2005 | 62 | 0.240 |
Why?
| Receptors, Adrenergic | 2 | 2001 | 14 | 0.240 |
Why?
| Stents | 3 | 2013 | 369 | 0.240 |
Why?
| Ventricular Function | 7 | 2005 | 18 | 0.240 |
Why?
| Predictive Value of Tests | 3 | 2013 | 995 | 0.230 |
Why?
| Myocardial Ischemia | 2 | 2006 | 128 | 0.230 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 155 | 0.230 |
Why?
| Mutation | 2 | 2008 | 1415 | 0.230 |
Why?
| Adrenergic beta-Agonists | 6 | 2001 | 45 | 0.230 |
Why?
| United States | 7 | 2018 | 5275 | 0.230 |
Why?
| Receptors, Androgen | 3 | 2005 | 51 | 0.230 |
Why?
| Muscle Cells | 1 | 2003 | 24 | 0.220 |
Why?
| Immunoglobulin Fab Fragments | 1 | 2002 | 21 | 0.220 |
Why?
| Gene Expression Regulation | 6 | 2006 | 1064 | 0.220 |
Why?
| Muscle Fibers, Skeletal | 2 | 2001 | 63 | 0.210 |
Why?
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 38 | 0.210 |
Why?
| Glucose | 1 | 2005 | 366 | 0.210 |
Why?
| Treatment Outcome | 5 | 2019 | 5558 | 0.210 |
Why?
| Muscle Contraction | 1 | 2003 | 115 | 0.210 |
Why?
| Cell Membrane | 4 | 2017 | 274 | 0.210 |
Why?
| Risk Factors | 6 | 2020 | 3906 | 0.200 |
Why?
| Apoptosis | 2 | 2005 | 1294 | 0.200 |
Why?
| Vasoconstrictor Agents | 1 | 2002 | 85 | 0.200 |
Why?
| Kinetics | 10 | 2010 | 696 | 0.190 |
Why?
| Female | 19 | 2019 | 28542 | 0.190 |
Why?
| Peptides | 1 | 2002 | 273 | 0.190 |
Why?
| Drug Therapy, Combination | 2 | 2013 | 420 | 0.190 |
Why?
| Mibefradil | 1 | 2000 | 1 | 0.190 |
Why?
| Estrogens, Non-Steroidal | 1 | 2000 | 16 | 0.180 |
Why?
| 5' Untranslated Regions | 1 | 2000 | 33 | 0.180 |
Why?
| Plants | 1 | 2000 | 41 | 0.180 |
Why?
| Adrenergic alpha-Agonists | 4 | 2001 | 20 | 0.170 |
Why?
| Maximum Tolerated Dose | 1 | 2019 | 37 | 0.170 |
Why?
| Phenylephrine | 4 | 2001 | 36 | 0.170 |
Why?
| Isoflavones | 1 | 2000 | 92 | 0.170 |
Why?
| Orchiectomy | 3 | 2004 | 50 | 0.170 |
Why?
| Middle Aged | 11 | 2019 | 12962 | 0.170 |
Why?
| Sulfonamides | 1 | 2000 | 141 | 0.170 |
Why?
| Administration, Intravenous | 1 | 2019 | 73 | 0.170 |
Why?
| Sex Factors | 2 | 2013 | 765 | 0.170 |
Why?
| Angiotensin II | 3 | 1999 | 162 | 0.170 |
Why?
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 6 | 1993 | 10 | 0.170 |
Why?
| Disability Evaluation | 1 | 2019 | 97 | 0.170 |
Why?
| Multivariate Analysis | 2 | 2013 | 642 | 0.160 |
Why?
| Nitric Oxide Donors | 1 | 1998 | 12 | 0.160 |
Why?
| Drug Administration Schedule | 1 | 2019 | 403 | 0.160 |
Why?
| Knee Prosthesis | 1 | 2019 | 57 | 0.160 |
Why?
| Recovery of Function | 1 | 2019 | 223 | 0.160 |
Why?
| Genetic Vectors | 2 | 2009 | 138 | 0.160 |
Why?
| Antibodies, Monoclonal | 1 | 2002 | 548 | 0.150 |
Why?
| Health Care Costs | 1 | 2019 | 186 | 0.150 |
Why?
| Base Sequence | 4 | 2005 | 724 | 0.150 |
Why?
| Women | 1 | 2017 | 32 | 0.150 |
Why?
| Animals, Newborn | 7 | 2007 | 410 | 0.150 |
Why?
| Logistic Models | 2 | 2013 | 985 | 0.150 |
Why?
| Risk Assessment | 2 | 2013 | 1343 | 0.150 |
Why?
| Double-Blind Method | 1 | 2019 | 737 | 0.150 |
Why?
| Schools, Medical | 1 | 2017 | 77 | 0.150 |
Why?
| Mitochondria, Heart | 4 | 2005 | 42 | 0.150 |
Why?
| Platelet Activation | 1 | 2017 | 50 | 0.140 |
Why?
| Blotting, Northern | 3 | 2002 | 120 | 0.140 |
Why?
| Epinephrine | 1 | 2017 | 107 | 0.140 |
Why?
| Signal Transduction | 3 | 2017 | 1742 | 0.140 |
Why?
| Minority Groups | 1 | 2017 | 137 | 0.140 |
Why?
| Nitric Oxide | 1 | 1998 | 294 | 0.140 |
Why?
| Endothelium, Vascular | 3 | 2004 | 285 | 0.140 |
Why?
| Receptors, Cholinergic | 1 | 1996 | 17 | 0.140 |
Why?
| Serotonin | 1 | 2017 | 160 | 0.140 |
Why?
| Delivery of Health Care | 1 | 2019 | 328 | 0.130 |
Why?
| Catecholamines | 3 | 1996 | 51 | 0.130 |
Why?
| Down-Regulation | 2 | 2008 | 382 | 0.130 |
Why?
| Algorithms | 3 | 2013 | 681 | 0.130 |
Why?
| Myocardial Infarction | 1 | 1999 | 406 | 0.130 |
Why?
| Benzofurans | 2 | 1992 | 18 | 0.130 |
Why?
| Education, Medical, Graduate | 1 | 2018 | 231 | 0.130 |
Why?
| Cardiotonic Agents | 2 | 2010 | 77 | 0.130 |
Why?
| Gene Expression Regulation, Developmental | 1 | 1996 | 150 | 0.130 |
Why?
| Myocytes, Smooth Muscle | 2 | 2008 | 92 | 0.130 |
Why?
| Ribonucleosides | 1 | 1994 | 2 | 0.120 |
Why?
| Aminoimidazole Carboxamide | 1 | 1994 | 3 | 0.120 |
Why?
| Thrombolytic Therapy | 2 | 2010 | 125 | 0.120 |
Why?
| Protein Isoforms | 3 | 2007 | 122 | 0.120 |
Why?
| Arthroplasty, Replacement, Knee | 1 | 2019 | 288 | 0.120 |
Why?
| Bradykinin | 3 | 1999 | 19 | 0.120 |
Why?
| DNA, Complementary | 2 | 2008 | 150 | 0.120 |
Why?
| Age Factors | 2 | 2013 | 1191 | 0.120 |
Why?
| Physicians | 1 | 2018 | 255 | 0.120 |
Why?
| Myocardial Reperfusion Injury | 1 | 1994 | 50 | 0.120 |
Why?
| Binding Sites | 6 | 2002 | 425 | 0.120 |
Why?
| Gene Expression | 5 | 2003 | 661 | 0.120 |
Why?
| Sodium | 4 | 1992 | 101 | 0.120 |
Why?
| Receptors, Adrenergic, beta-1 | 2 | 2004 | 7 | 0.110 |
Why?
| Receptors, Purinergic P2Y12 | 1 | 2013 | 13 | 0.110 |
Why?
| Cyclic AMP | 5 | 2000 | 104 | 0.110 |
Why?
| Dihydropyridines | 3 | 1993 | 10 | 0.110 |
Why?
| Heart Rate | 4 | 2001 | 351 | 0.110 |
Why?
| NAD | 2 | 2002 | 44 | 0.110 |
Why?
| Blood Pressure | 3 | 2006 | 553 | 0.110 |
Why?
| Therapy, Computer-Assisted | 1 | 2013 | 34 | 0.110 |
Why?
| Drug Resistance | 1 | 2013 | 73 | 0.110 |
Why?
| Calsequestrin | 3 | 2007 | 3 | 0.110 |
Why?
| Arkansas | 1 | 2019 | 2182 | 0.110 |
Why?
| Ethers, Cyclic | 1 | 1992 | 4 | 0.110 |
Why?
| Educational Measurement | 1 | 2014 | 232 | 0.110 |
Why?
| Smoking | 1 | 2017 | 553 | 0.110 |
Why?
| Tachycardia, Ventricular | 1 | 2013 | 43 | 0.110 |
Why?
| Tachycardia, Supraventricular | 1 | 2013 | 40 | 0.110 |
Why?
| Beriberi | 1 | 2012 | 7 | 0.110 |
Why?
| Ganglia, Sympathetic | 1 | 1992 | 3 | 0.110 |
Why?
| Cell Line | 2 | 2008 | 1125 | 0.100 |
Why?
| Defibrillators, Implantable | 1 | 2013 | 60 | 0.100 |
Why?
| Aged | 6 | 2019 | 9984 | 0.100 |
Why?
| Phosphodiesterase Inhibitors | 2 | 1988 | 25 | 0.100 |
Why?
| Cell Communication | 1 | 1992 | 70 | 0.100 |
Why?
| Drug Monitoring | 1 | 2012 | 83 | 0.100 |
Why?
| Protein Kinase C | 2 | 2002 | 75 | 0.100 |
Why?
| Lipoproteins, LDL | 3 | 2004 | 190 | 0.100 |
Why?
| Decision Support Techniques | 1 | 2012 | 74 | 0.100 |
Why?
| Prospective Studies | 2 | 2019 | 2539 | 0.100 |
Why?
| Odds Ratio | 1 | 2013 | 588 | 0.100 |
Why?
| Immunoblotting | 2 | 2002 | 129 | 0.100 |
Why?
| Oxadiazoles | 2 | 1989 | 13 | 0.100 |
Why?
| Electrocardiography | 1 | 2013 | 279 | 0.090 |
Why?
| Incidence | 2 | 2008 | 1077 | 0.090 |
Why?
| International Normalized Ratio | 1 | 2010 | 29 | 0.090 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 2 | 2001 | 56 | 0.090 |
Why?
| Diabetic Angiopathies | 1 | 2010 | 21 | 0.090 |
Why?
| Molecular Sequence Data | 3 | 2002 | 954 | 0.090 |
Why?
| Cholesterol, LDL | 1 | 2010 | 41 | 0.090 |
Why?
| Evidence-Based Medicine | 1 | 2012 | 276 | 0.090 |
Why?
| Cardiomyopathies | 3 | 2002 | 115 | 0.090 |
Why?
| Foramen Ovale, Patent | 1 | 2010 | 29 | 0.090 |
Why?
| Intracranial Hemorrhages | 1 | 2010 | 42 | 0.090 |
Why?
| Endarterectomy, Carotid | 1 | 2010 | 63 | 0.090 |
Why?
| Adenoviridae | 3 | 2007 | 60 | 0.090 |
Why?
| Thrombectomy | 1 | 2010 | 70 | 0.090 |
Why?
| 8-Bromo Cyclic Adenosine Monophosphate | 2 | 2000 | 3 | 0.090 |
Why?
| Action Potentials | 1 | 2010 | 149 | 0.090 |
Why?
| Gene Transfer Techniques | 1 | 2009 | 39 | 0.090 |
Why?
| Gene Targeting | 1 | 2009 | 33 | 0.090 |
Why?
| Warfarin | 1 | 2010 | 89 | 0.090 |
Why?
| Drug Prescriptions | 1 | 2010 | 100 | 0.080 |
Why?
| Prognosis | 2 | 2008 | 2074 | 0.080 |
Why?
| Percutaneous Coronary Intervention | 1 | 2013 | 327 | 0.080 |
Why?
| Rats, Inbred WKY | 1 | 2008 | 28 | 0.080 |
Why?
| Protein Modification, Translational | 1 | 2007 | 3 | 0.080 |
Why?
| Rats, Inbred SHR | 1 | 2008 | 35 | 0.080 |
Why?
| Protein Engineering | 1 | 2008 | 21 | 0.080 |
Why?
| Nifedipine | 4 | 1990 | 26 | 0.080 |
Why?
| Glasgow Coma Scale | 1 | 2008 | 49 | 0.080 |
Why?
| Spectrometry, Fluorescence | 2 | 2002 | 50 | 0.080 |
Why?
| Acidosis | 1 | 1988 | 41 | 0.080 |
Why?
| Cerebrovascular Disorders | 1 | 2008 | 52 | 0.080 |
Why?
| Mesenteric Arteries | 1 | 2008 | 45 | 0.080 |
Why?
| Atrial Fibrillation | 1 | 2010 | 194 | 0.080 |
Why?
| Medical Records | 1 | 2008 | 92 | 0.080 |
Why?
| Secondary Prevention | 1 | 2008 | 86 | 0.080 |
Why?
| Heart Diseases | 1 | 2010 | 235 | 0.080 |
Why?
| Triiodothyronine | 1 | 1987 | 29 | 0.080 |
Why?
| Anticoagulants | 1 | 2010 | 275 | 0.070 |
Why?
| Cholesterol | 1 | 2008 | 153 | 0.070 |
Why?
| Homeostasis | 4 | 2002 | 231 | 0.070 |
Why?
| Cell Culture Techniques | 2 | 2005 | 109 | 0.070 |
Why?
| Thrombosis | 1 | 2010 | 261 | 0.070 |
Why?
| Dogs | 3 | 2007 | 219 | 0.070 |
Why?
| Recombinant Fusion Proteins | 1 | 2008 | 208 | 0.070 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2013 | 486 | 0.070 |
Why?
| Cerebral Hemorrhage | 1 | 2008 | 112 | 0.070 |
Why?
| Propranolol | 3 | 1994 | 81 | 0.070 |
Why?
| Adrenergic beta-Antagonists | 3 | 2017 | 112 | 0.070 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2007 | 134 | 0.070 |
Why?
| Pyridones | 1 | 1987 | 43 | 0.070 |
Why?
| Aorta | 2 | 2005 | 174 | 0.070 |
Why?
| 1-Methyl-3-isobutylxanthine | 4 | 1998 | 9 | 0.070 |
Why?
| Verapamil | 5 | 1994 | 22 | 0.070 |
Why?
| Angina Pectoris | 1 | 1986 | 19 | 0.070 |
Why?
| Vasodilator Agents | 1 | 1987 | 102 | 0.070 |
Why?
| Drug Delivery Systems | 1 | 2008 | 142 | 0.070 |
Why?
| Adult | 9 | 2017 | 14279 | 0.070 |
Why?
| Arteriovenous Fistula | 1 | 1986 | 24 | 0.070 |
Why?
| Aortic Aneurysm | 1 | 1986 | 26 | 0.070 |
Why?
| Carotid Stenosis | 1 | 2006 | 67 | 0.070 |
Why?
| Vena Cava, Inferior | 1 | 1986 | 81 | 0.070 |
Why?
| Carrier Proteins | 1 | 2007 | 359 | 0.070 |
Why?
| Aortic Diseases | 1 | 1986 | 53 | 0.060 |
Why?
| Cytoskeleton | 1 | 1985 | 46 | 0.060 |
Why?
| Culture Media, Serum-Free | 1 | 2005 | 19 | 0.060 |
Why?
| Mannitol | 1 | 2005 | 14 | 0.060 |
Why?
| Alprenolol | 1 | 1985 | 1 | 0.060 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2005 | 20 | 0.060 |
Why?
| Hospital Mortality | 1 | 2008 | 457 | 0.060 |
Why?
| Cytoskeletal Proteins | 1 | 1985 | 57 | 0.060 |
Why?
| Restriction Mapping | 1 | 2005 | 36 | 0.060 |
Why?
| Tumor Necrosis Factors | 1 | 2004 | 10 | 0.060 |
Why?
| In Situ Nick-End Labeling | 1 | 2005 | 64 | 0.060 |
Why?
| Casein Kinase II | 1 | 2004 | 10 | 0.060 |
Why?
| DNA Primers | 1 | 2005 | 224 | 0.060 |
Why?
| Muscle, Smooth | 1 | 2004 | 69 | 0.060 |
Why?
| Tissue Distribution | 1 | 2005 | 178 | 0.060 |
Why?
| Cloning, Molecular | 1 | 2005 | 212 | 0.060 |
Why?
| bcl-X Protein | 1 | 2005 | 60 | 0.060 |
Why?
| Myosin Heavy Chains | 1 | 2004 | 22 | 0.060 |
Why?
| Coronary Artery Bypass | 2 | 2010 | 133 | 0.060 |
Why?
| Ligands | 1 | 2004 | 229 | 0.060 |
Why?
| Protein Structure, Tertiary | 1 | 2005 | 270 | 0.060 |
Why?
| Antihypertensive Agents | 2 | 2020 | 126 | 0.060 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2005 | 37 | 0.060 |
Why?
| Calcium Radioisotopes | 3 | 1989 | 7 | 0.060 |
Why?
| Temperature | 1 | 2004 | 176 | 0.060 |
Why?
| Pyridines | 1 | 1985 | 141 | 0.060 |
Why?
| Androgens | 1 | 2004 | 75 | 0.060 |
Why?
| Gonadal Steroid Hormones | 2 | 2003 | 46 | 0.060 |
Why?
| Osmolar Concentration | 3 | 1992 | 86 | 0.060 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 655 | 0.060 |
Why?
| Angiography | 1 | 1983 | 139 | 0.060 |
Why?
| DNA Footprinting | 1 | 2002 | 14 | 0.050 |
Why?
| Ion Channel Gating | 2 | 2006 | 43 | 0.050 |
Why?
| Proto-Oncogene Proteins c-ets | 1 | 2002 | 8 | 0.050 |
Why?
| Luminescent Proteins | 1 | 2003 | 63 | 0.050 |
Why?
| Diagnosis, Differential | 2 | 2013 | 1140 | 0.050 |
Why?
| Green Fluorescent Proteins | 1 | 2003 | 106 | 0.050 |
Why?
| Electrophoretic Mobility Shift Assay | 1 | 2002 | 76 | 0.050 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 2002 | 44 | 0.050 |
Why?
| Coculture Techniques | 2 | 2003 | 152 | 0.050 |
Why?
| Pulmonary Embolism | 1 | 1983 | 103 | 0.050 |
Why?
| Vasodilation | 1 | 2003 | 102 | 0.050 |
Why?
| Cardiac Pacing, Artificial | 2 | 1994 | 31 | 0.050 |
Why?
| Receptors, Nicotinic | 2 | 1992 | 80 | 0.050 |
Why?
| Lovastatin | 2 | 1993 | 9 | 0.050 |
Why?
| Proto-Oncogene Proteins | 1 | 2002 | 166 | 0.050 |
Why?
| Macrophages | 1 | 2004 | 400 | 0.050 |
Why?
| Proteins | 1 | 2005 | 378 | 0.050 |
Why?
| Chronic Disease | 2 | 2003 | 616 | 0.050 |
Why?
| Systole | 2 | 1990 | 72 | 0.050 |
Why?
| Acute Disease | 1 | 2002 | 407 | 0.050 |
Why?
| Phenylalanine | 2 | 1999 | 130 | 0.050 |
Why?
| Blotting, Western | 1 | 2003 | 671 | 0.050 |
Why?
| Chronotherapy | 1 | 2020 | 2 | 0.050 |
Why?
| Electrophysiology | 3 | 1996 | 84 | 0.050 |
Why?
| Pulmonary Artery | 1 | 2002 | 153 | 0.050 |
Why?
| Polymerase Chain Reaction | 2 | 2002 | 526 | 0.050 |
Why?
| Enzyme Inhibitors | 2 | 2000 | 442 | 0.050 |
Why?
| Isoquinolines | 1 | 2000 | 27 | 0.050 |
Why?
| Isradipine | 3 | 1993 | 5 | 0.050 |
Why?
| Hemorrhage | 1 | 2002 | 218 | 0.050 |
Why?
| Nuclear Proteins | 1 | 2002 | 266 | 0.050 |
Why?
| Biological Transport | 1 | 2001 | 184 | 0.050 |
Why?
| Culture Media | 3 | 1993 | 103 | 0.050 |
Why?
| Phytoestrogens | 1 | 2000 | 22 | 0.050 |
Why?
| Electrophoresis | 1 | 2000 | 18 | 0.050 |
Why?
| RNA, Antisense | 1 | 2000 | 10 | 0.050 |
Why?
| Genetic Complementation Test | 1 | 2000 | 54 | 0.050 |
Why?
| Luciferases | 1 | 2000 | 54 | 0.050 |
Why?
| Plant Preparations | 1 | 2000 | 39 | 0.050 |
Why?
| Inflammation | 1 | 2004 | 674 | 0.040 |
Why?
| Genes, Reporter | 1 | 2000 | 98 | 0.040 |
Why?
| Up-Regulation | 3 | 2017 | 491 | 0.040 |
Why?
| Drug Interactions | 1 | 2000 | 224 | 0.040 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 120 | 0.040 |
Why?
| Clinical Trials as Topic | 1 | 2002 | 494 | 0.040 |
Why?
| Stimulation, Chemical | 3 | 1990 | 30 | 0.040 |
Why?
| Decision Trees | 1 | 1999 | 26 | 0.040 |
Why?
| Lung | 1 | 1983 | 529 | 0.040 |
Why?
| Cell Nucleus | 1 | 2000 | 210 | 0.040 |
Why?
| Ribosomal Protein S6 Kinases | 1 | 1999 | 8 | 0.040 |
Why?
| Stress, Mechanical | 1 | 1979 | 96 | 0.040 |
Why?
| Transfection | 1 | 2000 | 397 | 0.040 |
Why?
| Canada | 1 | 2019 | 107 | 0.040 |
Why?
| Iloprost | 1 | 1998 | 4 | 0.040 |
Why?
| omega-N-Methylarginine | 1 | 1998 | 11 | 0.040 |
Why?
| Molsidomine | 1 | 1998 | 7 | 0.040 |
Why?
| Nitroprusside | 1 | 1998 | 11 | 0.040 |
Why?
| Sodium-Potassium-Exchanging ATPase | 2 | 1993 | 66 | 0.040 |
Why?
| Cyclic GMP | 1 | 1998 | 23 | 0.040 |
Why?
| Indomethacin | 1 | 1998 | 41 | 0.040 |
Why?
| Prosthesis Failure | 1 | 2019 | 114 | 0.040 |
Why?
| Transcription Factors | 1 | 2002 | 635 | 0.040 |
Why?
| Consensus Development Conferences as Topic | 1 | 2018 | 13 | 0.040 |
Why?
| Hypertrophy, Left Ventricular | 1 | 1998 | 36 | 0.040 |
Why?
| Prosthesis Design | 1 | 2019 | 257 | 0.040 |
Why?
| Osteoarthritis, Knee | 1 | 2019 | 105 | 0.040 |
Why?
| Propanolamines | 2 | 1988 | 15 | 0.040 |
Why?
| Research Support as Topic | 1 | 2018 | 50 | 0.040 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2017 | 9 | 0.040 |
Why?
| Transglutaminases | 1 | 2017 | 16 | 0.040 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 69 | 0.040 |
Why?
| Patch-Clamp Techniques | 1 | 1997 | 150 | 0.040 |
Why?
| Platelet Aggregation | 1 | 2017 | 77 | 0.040 |
Why?
| Polysaccharides | 1 | 2017 | 57 | 0.040 |
Why?
| Heart Failure | 2 | 1993 | 489 | 0.040 |
Why?
| Protein Transport | 1 | 2017 | 189 | 0.040 |
Why?
| Cell Division | 3 | 2003 | 341 | 0.040 |
Why?
| Cell Movement | 2 | 2003 | 264 | 0.030 |
Why?
| Protein Biosynthesis | 1 | 1998 | 271 | 0.030 |
Why?
| Enkephalins | 2 | 1986 | 6 | 0.030 |
Why?
| Glycosylation | 2 | 2007 | 110 | 0.030 |
Why?
| Tandem Mass Spectrometry | 1 | 2017 | 246 | 0.030 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2017 | 392 | 0.030 |
Why?
| Pindolol | 2 | 1985 | 4 | 0.030 |
Why?
| Calibration | 2 | 1992 | 63 | 0.030 |
Why?
| GTP-Binding Proteins | 2 | 1993 | 96 | 0.030 |
Why?
| Fluorescent Dyes | 2 | 1992 | 110 | 0.030 |
Why?
| Extracellular Space | 2 | 1993 | 42 | 0.030 |
Why?
| Purinergic P1 Receptor Antagonists | 1 | 1994 | 2 | 0.030 |
Why?
| Theophylline | 1 | 1994 | 21 | 0.030 |
Why?
| Curriculum | 1 | 2018 | 440 | 0.030 |
Why?
| Transforming Growth Factor beta | 1 | 1994 | 161 | 0.030 |
Why?
| Case-Control Studies | 1 | 2017 | 1205 | 0.030 |
Why?
| Cardiomyopathy, Dilated | 1 | 1993 | 38 | 0.030 |
Why?
| Caspases | 2 | 2005 | 146 | 0.030 |
Why?
| Cell Separation | 3 | 2005 | 99 | 0.030 |
Why?
| Phosphorylation | 2 | 2005 | 598 | 0.030 |
Why?
| Receptors, Drug | 1 | 1993 | 6 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 2 | 1988 | 1516 | 0.030 |
Why?
| Digoxin | 1 | 1993 | 21 | 0.030 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2013 | 54 | 0.030 |
Why?
| Cytological Techniques | 1 | 1992 | 15 | 0.030 |
Why?
| Magnesium | 1 | 1992 | 39 | 0.030 |
Why?
| Ouabain | 3 | 1993 | 28 | 0.030 |
Why?
| Internship and Residency | 1 | 2018 | 494 | 0.030 |
Why?
| Urinary Tract Infections | 1 | 2012 | 59 | 0.030 |
Why?
| Potassium | 3 | 1993 | 58 | 0.030 |
Why?
| Adenine Nucleotides | 1 | 1991 | 4 | 0.020 |
Why?
| Cyanides | 1 | 1991 | 5 | 0.020 |
Why?
| Potassium Chloride | 1 | 1991 | 20 | 0.020 |
Why?
| Disease Models, Animal | 2 | 1994 | 1654 | 0.020 |
Why?
| Lactates | 1 | 1991 | 31 | 0.020 |
Why?
| Electron Transport | 1 | 1991 | 29 | 0.020 |
Why?
| Cricetinae | 3 | 2002 | 209 | 0.020 |
Why?
| Deoxyglucose | 1 | 1991 | 36 | 0.020 |
Why?
| Rats, Inbred Strains | 1 | 1991 | 208 | 0.020 |
Why?
| Aorta, Abdominal | 2 | 1994 | 44 | 0.020 |
Why?
| Malnutrition | 1 | 2012 | 91 | 0.020 |
Why?
| Fluoresceins | 1 | 1990 | 12 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2013 | 929 | 0.020 |
Why?
| Thyroid Hormones | 1 | 1990 | 18 | 0.020 |
Why?
| Adenosine Triphosphate | 1 | 1991 | 247 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 1991 | 362 | 0.020 |
Why?
| Phenethylamines | 1 | 1989 | 8 | 0.020 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 74 | 0.020 |
Why?
| Hospitals, Veterans | 1 | 2010 | 127 | 0.020 |
Why?
| Tritium | 2 | 1993 | 53 | 0.020 |
Why?
| Infant | 1 | 1998 | 3884 | 0.020 |
Why?
| Tetrodotoxin | 1 | 1989 | 14 | 0.020 |
Why?
| Cardiac Catheterization | 2 | 1983 | 245 | 0.020 |
Why?
| Sodium Channels | 1 | 1989 | 22 | 0.020 |
Why?
| Depression, Chemical | 1 | 1988 | 14 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2013 | 1281 | 0.020 |
Why?
| Bupivacaine | 1 | 1989 | 29 | 0.020 |
Why?
| Energy Metabolism | 1 | 1991 | 306 | 0.020 |
Why?
| Lidocaine | 1 | 1989 | 51 | 0.020 |
Why?
| Heart Transplantation | 1 | 1993 | 317 | 0.020 |
Why?
| Aerobiosis | 1 | 1988 | 15 | 0.020 |
Why?
| Amiloride | 1 | 1988 | 14 | 0.020 |
Why?
| Aspirin | 1 | 2010 | 126 | 0.020 |
Why?
| Anaerobiosis | 1 | 1988 | 17 | 0.020 |
Why?
| Free Radicals | 1 | 1988 | 35 | 0.020 |
Why?
| Catalase | 1 | 1988 | 74 | 0.020 |
Why?
| Oxygen | 2 | 1982 | 360 | 0.020 |
Why?
| Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 1 | 2007 | 1 | 0.020 |
Why?
| Leupeptins | 1 | 2007 | 8 | 0.020 |
Why?
| Tunicamycin | 1 | 2007 | 16 | 0.020 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2007 | 29 | 0.020 |
Why?
| Ryanodine Receptor Calcium Release Channel | 1 | 2007 | 13 | 0.020 |
Why?
| COS Cells | 1 | 2007 | 81 | 0.020 |
Why?
| Cell Membrane Permeability | 2 | 1987 | 28 | 0.020 |
Why?
| Superoxide Dismutase | 1 | 1988 | 127 | 0.020 |
Why?
| Sarcolemma | 1 | 1987 | 2 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 1 | 1988 | 184 | 0.020 |
Why?
| Radioligand Assay | 1 | 1987 | 53 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2010 | 628 | 0.020 |
Why?
| Milrinone | 1 | 1987 | 10 | 0.020 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 150 | 0.020 |
Why?
| Binding, Competitive | 1 | 1987 | 115 | 0.020 |
Why?
| Proteasome Inhibitors | 1 | 2007 | 114 | 0.020 |
Why?
| Pulmonary Circulation | 2 | 1983 | 36 | 0.020 |
Why?
| Caspase 8 | 1 | 2005 | 13 | 0.020 |
Why?
| Phenotype | 2 | 2003 | 797 | 0.020 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2005 | 19 | 0.020 |
Why?
| Cats | 1 | 2005 | 82 | 0.020 |
Why?
| Membrane Potentials | 1 | 2006 | 142 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2006 | 311 | 0.020 |
Why?
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2005 | 22 | 0.020 |
Why?
| Heart Neoplasms | 1 | 1985 | 36 | 0.020 |
Why?
| Protein Conformation | 1 | 2006 | 192 | 0.020 |
Why?
| bcl-2-Associated X Protein | 1 | 2005 | 71 | 0.020 |
Why?
| Testosterone Propionate | 1 | 2005 | 2 | 0.020 |
Why?
| Guanylyl Imidodiphosphate | 1 | 1985 | 2 | 0.020 |
Why?
| Phosphoprotein Phosphatases | 1 | 2004 | 19 | 0.020 |
Why?
| Phosphates | 1 | 2004 | 51 | 0.020 |
Why?
| Carcinoma | 1 | 1985 | 156 | 0.010 |
Why?
| Ventilation-Perfusion Ratio | 1 | 1983 | 6 | 0.010 |
Why?
| Nitrendipine | 1 | 1983 | 1 | 0.010 |
Why?
| Echocardiography | 2 | 1993 | 392 | 0.010 |
Why?
| Diltiazem | 1 | 1983 | 11 | 0.010 |
Why?
| Evaluation Studies as Topic | 1 | 1983 | 111 | 0.010 |
Why?
| Radionuclide Imaging | 1 | 1983 | 139 | 0.010 |
Why?
| Thyroid Neoplasms | 1 | 1985 | 164 | 0.010 |
Why?
| Ion Exchange | 1 | 2002 | 1 | 0.010 |
Why?
| Pressure | 1 | 2003 | 116 | 0.010 |
Why?
| Risk | 1 | 1983 | 340 | 0.010 |
Why?
| Sex Characteristics | 1 | 2004 | 213 | 0.010 |
Why?
| Organ Size | 1 | 2002 | 245 | 0.010 |
Why?
| Hemodynamics | 1 | 1983 | 248 | 0.010 |
Why?
| Enzyme Activation | 1 | 2002 | 330 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2007 | 834 | 0.010 |
Why?
| Heart Atria | 2 | 1993 | 60 | 0.010 |
Why?
| Dihydroalprenolol | 1 | 1980 | 3 | 0.010 |
Why?
| Retrospective Studies | 1 | 2013 | 6511 | 0.010 |
Why?
| Pulse | 1 | 1979 | 15 | 0.010 |
Why?
| Oximetry | 1 | 1980 | 72 | 0.010 |
Why?
| Carotid Arteries | 1 | 1979 | 88 | 0.010 |
Why?
| Models, Biological | 1 | 2003 | 806 | 0.010 |
Why?
| Flavonoids | 1 | 1999 | 62 | 0.010 |
Why?
| Sirolimus | 1 | 1999 | 67 | 0.010 |
Why?
| Endothelium | 1 | 1998 | 46 | 0.010 |
Why?
| Postoperative Complications | 1 | 1983 | 1060 | 0.010 |
Why?
| Naloxone | 2 | 1986 | 78 | 0.010 |
Why?
| Prazosin | 1 | 1994 | 11 | 0.010 |
Why?
| Atrial Natriuretic Factor | 1 | 1994 | 22 | 0.010 |
Why?
| Culture Media, Conditioned | 1 | 1994 | 51 | 0.010 |
Why?
| Constriction, Pathologic | 1 | 1994 | 99 | 0.010 |
Why?
| Turkeys | 1 | 1993 | 11 | 0.010 |
Why?
| Computers | 1 | 1994 | 48 | 0.010 |
Why?
| Virulence Factors, Bordetella | 1 | 1993 | 8 | 0.010 |
Why?
| Pertussis Toxin | 1 | 1993 | 11 | 0.010 |
Why?
| Neoplasms | 1 | 1983 | 1340 | 0.010 |
Why?
| Fetal Blood | 1 | 1993 | 71 | 0.010 |
Why?
| Cattle | 1 | 1993 | 230 | 0.010 |
Why?
| Calcium-Transporting ATPases | 1 | 1992 | 14 | 0.010 |
Why?
| Ventricular Function, Left | 1 | 1993 | 165 | 0.010 |
Why?
| Fibroblasts | 1 | 1994 | 368 | 0.010 |
Why?
| Analysis of Variance | 1 | 1993 | 639 | 0.010 |
Why?
| Stroke Volume | 1 | 1993 | 130 | 0.010 |
Why?
| Cell Survival | 1 | 1993 | 671 | 0.010 |
Why?
| Mesocricetus | 1 | 1990 | 6 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1992 | 729 | 0.010 |
Why?
| Fura-2 | 1 | 1990 | 3 | 0.010 |
Why?
| Lanthanum | 1 | 1990 | 4 | 0.010 |
Why?
| Diastole | 1 | 1990 | 76 | 0.010 |
Why?
| Fluorescence | 1 | 1990 | 46 | 0.010 |
Why?
| Reference Values | 1 | 1990 | 355 | 0.010 |
Why?
| Adenosine Diphosphate Ribose | 1 | 1989 | 8 | 0.010 |
Why?
| Atrial Function | 1 | 1989 | 6 | 0.010 |
Why?
| Cholera Toxin | 1 | 1989 | 16 | 0.010 |
Why?
| Oxidative Phosphorylation | 1 | 1987 | 44 | 0.000 |
Why?
| Glycolysis | 1 | 1987 | 72 | 0.000 |
Why?
| Enkephalin, Methionine | 1 | 1986 | 5 | 0.000 |
Why?
| Oxygen Consumption | 1 | 1987 | 214 | 0.000 |
Why?
| Pulmonary Valve Stenosis | 1 | 1985 | 14 | 0.000 |
Why?
| Receptors, Opioid | 1 | 1985 | 19 | 0.000 |
Why?
| Aging | 1 | 1990 | 772 | 0.000 |
Why?
| Adolescent | 1 | 1992 | 6921 | 0.000 |
Why?
| Coronary Circulation | 1 | 1980 | 60 | 0.000 |
Why?
| Regional Blood Flow | 1 | 1980 | 114 | 0.000 |
Why?
| Hemoglobins | 1 | 1980 | 119 | 0.000 |
Why?
| Brain | 1 | 1985 | 1419 | 0.000 |
Why?
|
|
Marsh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|